Table 3.
(a) The proportion of clonotype sequence within all sequences of the same Vβ family in different subpopulations determined by oligonucleotide probing. (b) Clone size of individual clonotypes in different CD8+ subpopulations
| (a) % of clonotype sequence within all Vβ+ sequences | (b) Clone size in 106 CD8+ cells of each phenotype‡ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sorted cells | Sorted cells | ||||||||||
| Donor | Peptide | Clonotype | Vβ | Date of sample | Total CD8+ cells* | CD28– CD27– | CD28+ CD27+ | Background† | Total CD8+ cells* | CD28– CD27– | CD28+ CD27+ |
| H0018 | pp65 56 | 18B§ | 6.4 | 08/99 | 25% | 33% | 27% | 1.0% | ND | ||
| 11/99 | 13% | 17% | ND | 1.0% | |||||||
| 07/00 | 11% | 16% | 16% | 1.0% | |||||||
| 18C | 6.4 | 08/99 | 3% | 5% | 2% | 0.1% | ND | ||||
| 11/99 | 1% | 2% | ND | 0.0% | |||||||
| 07/00 | 0.6% | 1.4% | 0.7% | 0.0% | |||||||
| 18D | 6.4 | 08/99 | 15% | 23% | 4% | 1.1% | ND | ||||
| 11/99 | 29% | 43% | ND | 1.4% | |||||||
| 07/00 | 21% | 44% | 12% | 1.4% | |||||||
| gag 703.3 | 18A | 13.1 | 08/99 | 6% | 0.8% | 45% | 0.5% | 3100 | 160 | 9300 | |
| 11/99 | 1.2% | 0.8% | >43% | 0.2% | 700 | 140 | >700 | ||||
| 07/00 | 1.3% | 0.2% | 6.4% | 0.2% | 1000 | 40 | 1700 | ||||
| gag 7027 | 18E | Vα6 | 08/99 | 1.8% | 0.8% | 5% | 0.03% | ND | |||
| H0009 | pp65 69 | 9C | 13.1 | 08/99 | 13% | 3% | 0.2% | 2200 | 5100 | ||
| 08/01 | 54% | 15% | 0.2% | 1100 | 1800 | ||||||
| 03/02 | 63% | 53% | 0.2% | ND | ND | ||||||
| 12/02 | 59% | 47% | 0.2% | 5400 | 34900 | ||||||
| gag 728 | 9B | 22 | 08/99 | 0.5% | 0.4% | 0.3% | 0.1% | 260 | 40 | 80 | |
| 08/01 | 0.3% | 0.2% | 0.3% | 0.1% | 100 | 20 | 80 | ||||
| env 740.19 | 9A | 13.6 | 08/99 | 47% | 86% | 0.1% | 7100 | 108000 | |||
| 08/01 | 60% | 77% | 0.1% | 3600 | 166000 | ||||||
| 03/02 | 17% | 70% | 0.1% | 1400 | 50000 | ||||||
| 12/02 | 26% | 91% | 0.1% | 400 | 33700 | ||||||
Bold, samples derived prior to starting antiretroviral therapy.
*
Either derived from whole PBMC or CD16− depleted PBMC.
†
Background indicates the magnitude of non-specific binding of the clonotype-specific probe to amplified negative control cDNA.
‡
Calculated from percentage clonotype [shown in (a)] and percentage of CD8+ cells that are Vβ+ (see methods).
§
Cells of clonotypes 18A-D weere previously also found in both CD28−CD57− and CD28−CD57+ populations (23).